Arthritis Research Canada will be hosting its annual ARThritis Soirée on Thursday, May 26 at 7pm. The Soirée will take place at the Vancouver Club, located at 915 W. Hastings Street, Vancouver. This gala will raise money for arthritis research, awareness, and advocacy. The concept behind the gala is that research has shown that art adds to one’s well-being. For many, it is a key element of managing chronic pain. Each year, the Soirée features one form of art. This year’s feature is the Art of Fencing with Olympic and World Champions.
The ARThritis Soirée is an evening designed to attract the city’s most prominent business and community leaders, philanthropists, doctors, scientists, healthcare professionals, and donors through an appreciation of art and a desire to support arthritis research.
The evening’s event will be emceed by Fred Lee, CBC, Vancouver Courier and The Province’s Man About Town. Guests can enjoy hors d’oeuvres, champagne, premium spirits and exquisite BC wines from LaStella and Le Vieux Pin wineries and indulge in legendary Joe Fortes oysters and Northern Divine Caviar.
There will be a live and silent auction, with items such as a chef’s table experience at Joe Fortes, photo sessions, paintings, and entertainment, vacation, spa and lifestyle packages. Buy your raffle ticket for a chance to win a beautiful Birk’s diamond necklace. Please note guests will have complimentary valet parking. Tickets to The 2016 ARThritis Soirée is available for $245.00 and includes complementary valet parking and a partial tax receipt. To learn more about the event, please click here.
Arthritis Research Canada would like to evaluate the effectiveness of Employment and Arthritis: Making it Work – an online eLearning program designed to help people with inflammatory arthritis stay employed. To do so, they are looking for participants to join a randomized controlled trial to evaluate the aforementioned program.
A team of student engineers from William Marsh Rice University, a private research university located in Houston, Texas, has developed a robotic horse that may help patients with arthritis. Based on the premise of hippotherapy, also known as equine-assisted therapy, the horse simulator is a robotic horse that can be ridden indoors anytime.
Hippotherapy relies on horses to improve the symptoms of patients with neurological or physical illnesses like autism, cerebral palsy, and arthritis. The rhythmic, swinging motion passes through the entire body and is thought to enhance balance, coordination and motor development. This form of treatment is prohibitive because of its cost and accessibility. Physical therapy sessions with a horse can cost upwards of $150 an hour. Continue reading →
A research team from the University of Calgary and Statistics Canada found that people living with osteoarthritis (OA) have almost twice the risk of losing work time due to illness or disability as those without OA. Furthermore, the researchers found that people with OA are three times as likely to become unemployed.
Combining the National Population Health Survey, the researchers selected 659 people with OA, matched them with 2,144 non-OA individuals on the basis of age and sex, and compared their reported work time loss from 2000 to 2010. Work time loss was 90% higher and unemployment tripled due to illness or disability among the OA patients after adjusting for sociodemographic, health and work-related status.
Osteoarthritis is by far the most common type of arthritis. It is estimated to affect more than 3,200,000 Canadians-about 1 in 10. The disease is the leading cause of chronic pain and loss of mobility in Canada and is associated strongly with diminished productivity and increased utilization of healthcare resources. Disease onset usually occurs during the working years. Continue reading →
A recent study published in the journal Arthritis & Rheumatology concluded that disease-modifying anti rheumatic drugs (DMARDs) may influence rheumatoid arthritis (RA) patients’ weight. The study looked at four DMARDs, including methotrexate, leflunomide, prednisone and tutor necrosis factor inhibitors (TNFis).
Researcher Joshua F. Baker and his team at the Philadelphia VA Medical Centre in Pennsylvania assessed how primary RA therapies influence changes in body mass index (BMI). A low BMI is one of the adverse long-term outcome in RA and disease-related weight loss may be the result of RA symptoms or treatment therapy.
The team used three large administrative databases to identify 32,859 RA patients who received treatment with methotrexate, leflunomide, prednisone and TNFis. Researchers also assessed independent factors that may affect the study outcome, including the patient’s age, sex, race, BMI, seropositivity* for anticyclic citrullinated peptides (CCP), diabetes, current smoking habits, comorbidities, C-reactive protein (CRP) levels, interstitial or other lung disease, malignancies, history of myocardial infarction, chronic kidney disease, and other factors.